AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NOVA EYE MEDICAL LTD

0.170

0.000

Volume:66.98K

Turnover:11.22K

Market Cap:48.42M

PE:-4.64

High:0.170

Open:0.165

Low:0.165

Close:0.170

52wk High:0.205

52wk Low:0.086

Shares:284.83M

Float Shares:240.54M

Volume Ratio:0.38

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.037

EPS(LYR):-0.037

ROE:-44.96%

ROA:-19.92%

PB:2.55

PE(LYR):-4.64

Loading ...

Overview Company News Filings

Assessing National Vision Holdings (EYE) Valuation After Recent Share Price Volatility

Simply Wall St.

BRIEF-Nova Eye Medical Posts December Quarter Sales Of $6.1 Million

Nova Eye Medical - December Quarter Sales of US$6.1 Mln

THOMSON REUTERS

Nova Eye Medical Says Statistical Report Backs Efficacy, Safety of Eye Surgery Device; Shares Up 3%

MT Newswires Live

There's No Escaping Nova Eye Medical Limited's (ASX:EYE) Muted Revenues Despite A 28% Share Price Rise

Simply Wall St.

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live

GUIDANCE: (EYE) National Vision Expects Fiscal 2025 Net Revenue Range $1.97B - $1.99B, vs. FactSet Est of $1.98B

MT Newswires Live

BRIEF-Nova Eye Medical Posts December Quarter Global Sales Of $6.1 Million

Nova Eye Medical Ltd - December Quarter Global Sales of US$6.1 Mln

THOMSON REUTERS

Nova Eye Medical Limited (ASX:EYE) Looks Inexpensive But Perhaps Not Attractive Enough

Simply Wall St.

A Look at National Vision (EYE)'s Valuation After New Growth Blueprint and 2025 Outlook Reaffirmation

Simply Wall St.

Nova Eye Medical Ltd. publishes 24-month iTrack data on canaloplasty for glaucoma treatment

National Vision Reaffirms 2025 Outlook

MT Newswires Live

What National Vision Holdings (EYE)'s Raised Revenue Outlook and Store Expansion Plans Mean For Shareholders

Simply Wall St.

The Bull Case For National Vision Holdings (EYE) Could Change Following a Return to Quarterly Profitability

Simply Wall St.

National Vision Holdings (EYE): Evaluating the Valuation After a Strong Year-to-Date Share Price Surge

Simply Wall St.

Nova Eye Medical Ltd-Quarterly Activities/Appendix 4C Cash Flow Report

THOMSON REUTERS

BUZZ-Australia's Nova Eye Medical jumps to 8-month high on NMPA approval

Nova Eye Medical - Nmpa China Approved Registration of Itrack Advance

THOMSON REUTERS

Nova Eye Medical Ltd.’s iTrack™ Canaloplasty to Be Featured at German Society of Ophthalmology Congress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EYE.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EYE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"EYE.AU\",,,,,undefined,":{"symbol":"EYE.AU","market":"AU","secType":"STK","nameCN":"NOVA EYE MEDICAL LTD","latestPrice":0.17,"timestamp":1771564320000,"preClose":0.17,"halted":0,"volume":66977,"delay":0,"changeRate":0,"nameEN":"NOVA EYE MEDICAL LTD","floatShares":240542047,"shares":284833284,"eps":-0.036626,"marketStatus":"Market Closed","change":0,"latestTime":"02-20 16:12:00 AEDT","open":0.165,"high":0.17,"low":0.165,"amount":11223,"amplitude":0.029412,"askPrice":0.17,"askSize":85624,"bidPrice":0.165,"bidSize":85593,"shortable":3,"etf":0,"ttmEps":-0.036626,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771801200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.17,"openAndCloseTimeList":[[1771542000000,1771563600000]],"volumeRatio":0.37808755258629567,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"EYE.AU\",,,,,undefined,":{"symbol":"EYE.AU","floatShares":240542047,"roa":"-19.92%","roe":"-44.96%","lyrEps":-0.036626,"volumeRatio":0.37808755258629567,"shares":284833284,"dividePrice":0,"high":0.17,"amplitude":0.029412,"preClose":0.17,"low":0.165,"week52Low":0.086,"pbRate":"2.55","psRate":"1.65","week52High":0.205,"institutionHeld":0,"latestPrice":0.17,"committee":-0.000181,"eps":-0.036626,"divideRate":0,"volume":66977,"delay":0,"ttmEps":-0.036626,"open":0.165,"prevYearClose":0.132,"prevWeekClose":0.165,"prevMonthClose":0.185,"prevQuarterClose":0.132,"fiveDayClose":0.165,"twentyDayClose":0.17,"sixtyDayClose":0.13,"dividendGrowthYears":0,"dividendGrowthRate":-1,"fiveYearAvgDividendRate":1.3621794871794872},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EYE.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-01","symbol":"EYE.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1769900400000,"name":null,"time":"","dateTimestamp":1769864400000,"actualEps":null},{"date":"2025-10-27","symbol":"EYE.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761519600000,"name":null,"time":"","dateTimestamp":1761483600000,"actualEps":null},{"market":"AU","date":"2024-02-13","symbol":"EYE.AU","defaultRemindTime":1707778800000,"type":"split","dateTimestamp":1707742800000,"forFactor":973737,"toFactor":1000000,"ratio":0.973737},{"date":"2023-08-28","symbol":"EYE.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null},{"date":"2023-02-27","symbol":"EYE.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1677452400000,"name":null,"time":"","dateTimestamp":1677416400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EYE.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-07-21","recordDate":"2020-07-22","paymentDate":"2020-07-29","value":0.135,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EYE.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612283266","title":"Assessing National Vision Holdings (EYE) Valuation After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2612283266","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612283266?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:26","pubTimestamp":1771511170,"startTime":"0","endTime":"0","summary":"Event context and recent share moves\nNational Vision Holdings (EYE) has been trading without a specific headline catalyst, so recent price action offers the clearest signal for investors watching the optical retail name.\nThe stock closed at $27.06, with a 1 day return of 2.52% decline, 7 day return of 4.01% decline and roughly flat performance over the past month. Over the past 3 months, the share price shows a 10.04% gain. The 1 year total return is 118.40%, alongside a 3 year total return...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/assessing-national-vision-holdings-eye-valuation-after-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/assessing-national-vision-holdings-eye-valuation-after-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK7007","LU0566484027.USD","LU1559883803.SGD","LU0053671581.USD","BK4200","EYE.AU","EYE"],"gpt_icon":0},{"id":"2607720460","title":"BRIEF-Nova Eye Medical Posts December Quarter Sales Of $6.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2607720460","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607720460?lang=en_us&edition=fundamental","pubTime":"2026-01-29 09:30","pubTimestamp":1769650252,"startTime":"0","endTime":"0","summary":"BRIEF-Nova Eye Medical Posts December Quarter Sales Of $6.1 MillionJan 29 (Reuters) - Nova Eye Medical Ltd EYE.AX:DECEMBER QUARTER SALES OF US$6.1 MILLIONFurther company coverage: EYE.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YT16G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EYE.AU","BK7007"],"gpt_icon":0},{"id":"2607738723","title":"Nova Eye Medical - December Quarter Sales of US$6.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2607738723","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607738723?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:45","pubTimestamp":1769636700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT16G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EYE.AU","BK7007"],"gpt_icon":0},{"id":"2606272168","title":"Nova Eye Medical Says Statistical Report Backs Efficacy, Safety of Eye Surgery Device; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606272168","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606272168?lang=en_us&edition=fundamental","pubTime":"2026-01-27 12:57","pubTimestamp":1769489877,"startTime":"0","endTime":"0","summary":"Nova Eye Medical  said the success rate in intraocular pressure reduction in patients with baseline intraocular pressure greater than 18 millimeters of mercury  was 85% in its 2025 statistical report on progress of patients in the iTrack Global Data Registry, an independently managed database, according to a Tuesday Australian bourse filing.Over 400 eyes reached the 12-month follow-up point under the registry, the filing said. Patients experienced a mean 40% reduction in medication burden across the group. There were six reported adverse events.The outcomes were considered clinically meaningful, per the filing, compared with other minimally invasive glaucoma surgery procedures.Nova Eye Medical's shares rose nearly 3% in recent trading on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EYE.AU","BK7007"],"gpt_icon":0},{"id":"2604616582","title":"There's No Escaping Nova Eye Medical Limited's (ASX:EYE) Muted Revenues Despite A 28% Share Price Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2604616582","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604616582?lang=en_us&edition=fundamental","pubTime":"2026-01-20 06:28","pubTimestamp":1768861702,"startTime":"0","endTime":"0","summary":"Nova Eye Medical Limited ( ASX:EYE ) shareholders would be excited to see that the share price has had a great month...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-eye/nova-eye-medical-shares/news/theres-no-escaping-nova-eye-medical-limiteds-asxeye-muted-re","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-eye/nova-eye-medical-shares/news/theres-no-escaping-nova-eye-medical-limiteds-asxeye-muted-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EYE.AU","EYE","ELXMF"],"gpt_icon":0},{"id":"2603680631","title":"Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2603680631","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603680631?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:17","pubTimestamp":1768313834,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF  advancing by 0.1% and the iShares Biotechnology ETF  down 0.2%.Cardinal Health  shares were up more than 3% after the company said it now expects at least $10 in fiscal 2026 non-GAAP earnings per diluted share, up from its prior outlook of $9.65 to $9.85.Argenx  stock was up more than 1% after the company said its supplemental biologics license application for Vyvgart has received the US Food and Drug Administration's acceptance for priority review to treat adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis.National Vision  shares were down more than 6% after the company said it continues to expect fiscal 2025 adjusted earnings of $0.63 to $0.71 per diluted share and revenue of between $1.97 billion and $1.99 billion.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4175","BK4581","LU0072461881.USD","LU0792757196.USD","ARGX","LU1267930490.SGD","BK4200","LU0320765992.SGD","BK4139","IE00BJJMRZ35.SGD","LU0006061336.USD","LABU","LU0052756011.USD","LU1571399168.USD","XLV","LU0211327993.USD","LU1267930227.SGD","IBB","BK7007","BK4505","LU0053671581.USD","IE0002141913.USD","XBI","LU0162691827.USD","LU1983260115.SGD","EYE.AU","LU0154236417.USD","LU0310799852.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0310800965.SGD","IE00BFTCPJ56.SGD","LU0566484027.USD","LU2324357040.USD","LU0889566641.SGD","CAH","LU1880398554.USD","LU0109394709.USD","LU0211328371.USD","SG9999001440.SGD","IE00B4R5TH58.HKD","BK4585","LU1267930813.SGD","LU1880398471.USD","LU0889565916.HKD","LU0128525689.USD","IE00BJT1NW94.SGD","IE0034235188.USD","BK4588","EYE"],"gpt_icon":0},{"id":"2603686967","title":"GUIDANCE: (EYE) National Vision Expects Fiscal 2025 Net Revenue Range $1.97B - $1.99B, vs. FactSet Est of $1.98B","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686967","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686967?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:04","pubTimestamp":1768305847,"startTime":"0","endTime":"0","summary":"GUIDANCE: (EYE) National Vision Expects Fiscal 2025 Net Revenue Range $1.97B - $1.99B, vs. FactSet Est of $1.98B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EYE","EYE.AU"],"gpt_icon":0},{"id":"2602569297","title":"BRIEF-Nova Eye Medical Posts December Quarter Global Sales Of $6.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602569297","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602569297?lang=en_us&edition=fundamental","pubTime":"2026-01-12 09:20","pubTimestamp":1768180857,"startTime":"0","endTime":"0","summary":"BRIEF-Nova Eye Medical Posts December Quarter Global Sales Of $6.1 MillionJan 12 (Reuters) - Nova Eye Medical Ltd EYE.AX:DECEMBER QUARTER GLOBAL SALES OF US$6.1 MILLIONFurther company coverage: EYE.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YA0ZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","EYE.AU"],"gpt_icon":0},{"id":"2602563673","title":"Nova Eye Medical Ltd -  December Quarter Global Sales of US$6.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563673?lang=en_us&edition=fundamental","pubTime":"2026-01-12 06:47","pubTimestamp":1768171642,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nFWN3YA0ZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","EYE.AU"],"gpt_icon":0},{"id":"2589849250","title":"Nova Eye Medical Limited (ASX:EYE) Looks Inexpensive But Perhaps Not Attractive Enough","url":"https://stock-news.laohu8.com/highlight/detail?id=2589849250","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589849250?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:25","pubTimestamp":1764973558,"startTime":"0","endTime":"0","summary":"You may think that with a price-to-sales (or \"P/S\") ratio of 1.4x Nova Eye Medical Limited ( ASX:EYE ) is definitely a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-eye/nova-eye-medical-shares/news/nova-eye-medical-limited-asxeye-looks-inexpensive-but-perhap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-eye/nova-eye-medical-shares/news/nova-eye-medical-limited-asxeye-looks-inexpensive-but-perhap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1559883803.SGD","LU0053671581.USD","LU0566484027.USD","BK7007","EYE","EYE.AU","BK4082","BK4200","ELXMF"],"gpt_icon":0},{"id":"2587375446","title":"A Look at National Vision (EYE)'s Valuation After New Growth Blueprint and 2025 Outlook Reaffirmation","url":"https://stock-news.laohu8.com/highlight/detail?id=2587375446","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587375446?lang=en_us&edition=fundamental","pubTime":"2025-11-29 11:17","pubTimestamp":1764386246,"startTime":"0","endTime":"0","summary":"National Vision Holdings (EYE) laid out an ambitious plan for the next five years, highlighting a disciplined investment approach, a phased transformation, and significant store expansion. The company also reaffirmed its fiscal 2025 earnings outlook. Investors now have a clearer view of management's roadmap through 2030.\nSee our latest analysis for National Vision Holdings.\nNational Vision Holdings’ bold transformation plans come amid strong momentum for the stock, with a 167.9% share price...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/a-look-at-national-vision-eyes-valuation-after-new-growth-bl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/a-look-at-national-vision-eyes-valuation-after-new-growth-bl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EYE.AU","LU0053671581.USD","LU0566484027.USD","LU1559883803.SGD","BK4200","EYE","BK7007"],"gpt_icon":0},{"id":"2584399465","title":"Nova Eye Medical Ltd. publishes 24-month iTrack data on canaloplasty for glaucoma treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2584399465","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584399465?lang=en_us&edition=fundamental","pubTime":"2025-11-19 12:32","pubTimestamp":1763526735,"startTime":"0","endTime":"0","summary":"Nova Eye Medical Ltd. published a document presenting 18-24 month data from the iTrack Global Data Registry related to canaloplasty for the treatment of glaucoma. The document includes results on patient demographics, glaucoma stage, diagnosis, procedures performed, device types used, and reported outcomes and complications. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nova Eye Medical Ltd. published the original content used to generate this news brief on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL78Fkbx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EYE.AU","BK7007"],"gpt_icon":0},{"id":"2584862820","title":"National Vision Reaffirms 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2584862820","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584862820?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:24","pubTimestamp":1763382289,"startTime":"0","endTime":"0","summary":"National Vision  reaffirmed Monday its previous fiscal 2025 outlook of net revenue increase in the high-single-digits.The company said it has launched a multi-year plan for about $20 million, half of which is expected in fiscal 2026.The projected savings come primarily from renegotiating vendor pricing, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0053671581.USD","LU1559883803.SGD","BK4200","LU0566484027.USD","EYE","EYE.AU","BK7007"],"gpt_icon":0},{"id":"2583842526","title":"What National Vision Holdings (EYE)'s Raised Revenue Outlook and Store Expansion Plans Mean For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2583842526","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583842526?lang=en_us&edition=fundamental","pubTime":"2025-11-14 10:17","pubTimestamp":1763086675,"startTime":"0","endTime":"0","summary":"In early November 2025, National Vision Holdings reported that it remained on track to open 32 new stores during fiscal 2025, with a net addition of 9 stores after planned closures, and posted strong third-quarter earnings with revenue rising to US$487.33 million and net income of US$3.37 million.\nThe company also raised its full-year net revenue guidance to a range of US$1.97 billion to US$1.99 billion, reflecting increased confidence in its ongoing business performance.\nWe'll examine how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/what-national-vision-holdings-eyes-raised-revenue-outlook-an","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/what-national-vision-holdings-eyes-raised-revenue-outlook-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EYE.AU","EYE"],"gpt_icon":0},{"id":"2581705108","title":"The Bull Case For National Vision Holdings (EYE) Could Change Following a Return to Quarterly Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2581705108","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581705108?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:37","pubTimestamp":1762357024,"startTime":"0","endTime":"0","summary":"National Vision Holdings, Inc. reported third quarter 2025 earnings, moving from a net loss to a net income of US$3.37 million on revenues of US$487.33 million, both up from the same period last year.\nThe company’s return to profitability and increased revenue highlight improved operational performance and suggest enhanced demand across its service offerings.\nWe’ll explore how National Vision’s shift to positive earnings this quarter could reshape its future investment outlook and business...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/the-bull-case-for-national-vision-holdings-eye-could-change","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/the-bull-case-for-national-vision-holdings-eye-could-change","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0566484027.USD","BK4200","LU0053671581.USD","BK7007","LU1559883803.SGD","EYE.AU","EYE"],"gpt_icon":0},{"id":"2580253610","title":"National Vision Holdings (EYE): Evaluating the Valuation After a Strong Year-to-Date Share Price Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2580253610","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580253610?lang=en_us&edition=fundamental","pubTime":"2025-11-03 07:17","pubTimestamp":1762125426,"startTime":"0","endTime":"0","summary":"National Vision Holdings (EYE) shares recently moved as investors reassessed the company’s position in the retail eye care space. The stock’s performance over the past month has reflected a shift in sentiment, as ongoing industry developments have attracted attention.\nSee our latest analysis for National Vision Holdings.\nAfter a surge earlier this year, National Vision Holdings’ share price has cooled off a bit, pulling back over the past month but still boasting a remarkable year-to-date...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/national-vision-holdings-eye-evaluating-the-valuation-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/retail/nasdaq-eye/national-vision-holdings/news/national-vision-holdings-eye-evaluating-the-valuation-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EYE.AU","LU0053671581.USD","LU0566484027.USD","LU1559883803.SGD","BK4200","EYE","BK7007"],"gpt_icon":0},{"id":"2579010322","title":"Nova Eye Medical Ltd-Quarterly Activities/Appendix 4C Cash Flow Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2579010322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579010322?lang=en_us&edition=fundamental","pubTime":"2025-10-31 05:27","pubTimestamp":1761859639,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUE8MG5DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EYE.AU","BK7007"],"gpt_icon":0},{"id":"2571398969","title":"BUZZ-Australia's Nova Eye Medical jumps to 8-month high on NMPA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2571398969","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571398969?lang=en_us&edition=fundamental","pubTime":"2025-09-30 09:24","pubTimestamp":1759195477,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Nova Eye Medical jumps to 8-month high on NMPA approval** Shares of Australia's Nova Eye Medical EYE.AX rise as much as 16.6% to A$0.170; their highest since January 28** Ophthalmic t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nL6N3VH02G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","EYE.AU"],"gpt_icon":0},{"id":"2571361698","title":"Nova Eye Medical - Nmpa China Approved Registration of Itrack Advance","url":"https://stock-news.laohu8.com/highlight/detail?id=2571361698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571361698?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:25","pubTimestamp":1759188328,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EYE.AU","BK7007"],"gpt_icon":0},{"id":"2570605046","title":"Nova Eye Medical Ltd.’s iTrack™ Canaloplasty to Be Featured at German Society of Ophthalmology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2570605046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570605046?lang=en_us&edition=fundamental","pubTime":"2025-09-25 13:53","pubTimestamp":1758779638,"startTime":"0","endTime":"0","summary":"Nova Eye Medical Ltd. will participate in the 2025 DOG Annual Congress, held September 25-28 in Berlin, Germany. The company will present results from the iTrack Global Data Registry, highlighting the role of its iTrack canaloplasty technology for the treatment of glaucoma. The presentation will be delivered by Dr. Karsten Klabe and co-authors on September 27 during the \"Glaucoma - Modern Diagnostics\" session.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nova Eye Medical Ltd. published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDL146Q2L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EYE.AU","BK7007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}